Hims & Hers (HIMS) Stock Pops 13% As FDA Gives Peptide the Green Light

TLDR

• HIMS surged up to 13% after an FDA advisory panel voted 8-6 to recommend adding BPC-157 to the 503A Bulks List
• The vote allows state-licensed compounding pharmacies to produce BPC-157, opening a potential new revenue stream for Hims
• The outcome surprised markets — earlier FDA briefing notes had flagged safety concerns and hinted at a rejection
• Citi raised its price target to $35 (from $28) but cautioned that near-term upside may be limited heading into August 10 earnings
• Canaccord Genuity reiterated a Buy rating and $40 price target, calling peptide reclassification a positive for the thesis

Hims & Hers Health jumped as much as 13% on Thursday after an FDA advisory panel voted to recommend loosening restrictions on BPC-157, a popular peptide compound. The stock was trading around $32.75 at the time, giving the company a market cap of $7.6 billion.

Hims & Hers Health, Inc., HIMS

The FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to add BPC-157 to the 503A Bulks List. That means state-licensed compounding pharmacies can now make custom versions of the peptide for patients.

… Continue reading the full article at the original source below.